Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masoud Azizad

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Vaccine|July 27, 2025
A phase 3 randomized, double-blind clinical study to evaluate the safety and immunogenicity of V116 when administered concomitantly with influenza vaccine in adults 50 years of age or olderTosin Omole, Aaron S Weinberg, Masoud Azizad, et al.
The New England Journal of Medicine|May 28, 2024
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed HyperlipidemiaChristie M Ballantyne, Szilard Vasas, Masoud Azizad, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 31, 2021
A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral LoadMichael Dougan, Masoud Azizad, Bharat Mocherla, et al.
The New England Journal of Medicine|July 14, 2021
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19Michael Dougan, Ajay Nirula, Masoud Azizad, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Vaccine|July 27, 2025
A phase 3 randomized, double-blind clinical study to evaluate the safety and immunogenicity of V116 when administered concomitantly with influenza vaccine in adults 50 years of age or olderTosin Omole, Aaron S Weinberg, Masoud Azizad, et al.
The New England Journal of Medicine|May 28, 2024
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed HyperlipidemiaChristie M Ballantyne, Szilard Vasas, Masoud Azizad, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 31, 2021
A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral LoadMichael Dougan, Masoud Azizad, Bharat Mocherla, et al.
The New England Journal of Medicine|July 14, 2021
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19Michael Dougan, Ajay Nirula, Masoud Azizad, et al.
Pageof 1